Replimune Group’s REPL share price tumbled 54.2% over the past three months. The massive setback was observed after the FDA issued a complete response letter (CRL) in July, against the biologics ...
Fintel reports that on September 19, 2025, JP Morgan downgraded their outlook for Replimune Group (NasdaqGS:REPL) from Neutral to Underweight. Analyst Price Forecast Suggests 110.57% Upside As of ...
A crucial meeting with a regulator didn't seem to go well. It was about a leading pipeline drug being developed by the company. The meeting was conducted with U.S. Food and Drug Administration (FDA) ...
ABC‘s decision to pull “Jimmy Kimmel Live!” from its network indefinitely sent shockwaves through the media industry and political world, with commentators criticizing the decision as an act of ...
Juliette Binoche won an Oscar for the “The English Patient;” has worked with the greatest auteurs, from Leos Carax to Abbas Kiarostami and Olivier Assayas; and has presided over Cannes and Berlin ...
TIOBE Index for October 2025: Top 10 Most Popular Programming Languages Your email has been sent The October TIOBE Programming Community Index brought a few quiet but meaningful shifts. Python remains ...
Russian https://github.com/iliakan/javascript-tutorial-ru @iliakan * https://learn.javascript.ru Turkish https://github.com/sahinyanlik/javascript-tutorial-tr ...
Biggest stock losers Replimune Group (REPL) -38% - Shares plunged after the biotech firm said it held a Type A meeting with the FDA to discuss the complete response letter for its BLA seeking ...